Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
| 适应症 | FSGS |
|---|---|
| 分期 | 3期 |
| 申办方 | University of Colorado, Denver |
| 状态 | 已完成 |
| 受试者人数 | 15 人 |
| 干预（药物） | Acthar |
| 开始日期 | 2019年2月1日 |
| 完成日期 | 2024年6月6日 |
| 结果公布日 | 2020年3月24日 |
摘要
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria
| One Arm | 14 Participants |
|---|
Rate of Recurrence of Proteinuria
| One Arm | 3 Participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
- Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
- Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
- Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
- High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. — University of Florida